Mayo Clinic has had a long-standing commitment to support and lead NCTN clinical trials through NCCTG, ECOG, ACOSOG, ACRIN, RTOG, and GOG. Mayo Clinic served as the founding institution and operational base for NCCTG until its merger with CALGB and ACOSOG to form the Alliance. Mayo investigators have also had leadership roles in these groups as well as in the newly forming groups (Alliance, ECOG-ACRIN, and NRG). The current clinical research structure within the Mayo Clinic Cancer Center (MCCC) continues to prioritize NIH sponsored trial, including NCTN trials, over other trials. Support systems are in place within the MCCC to maximize accrual and to support the translational components of these trials, including biospecimen collection and imaging. Mayo investigators also remained very active in trial leadership. Mayo investigators have also been very effective in utilizing data and biospecimens collected from NCTN trials to address important and relevant research questions. Through this commitment to research, Mayo investigators have published multiple reports in high impact journals and successfully obtained multiple grants, including R01 grants, to support this work.
The U10 Network Lead Academic Participating Site Grant provides the infrastructure support to perform NCTN clinical trials at Mayo Clinic and the activities related to our participation in the NCTN groups Alliance, ECOG-ACRIN, and NRG. Mayo Clinic intends to remain one of the leading sites in accrual to NCTN clinical trials as well as to continue in key leadership and scientific roles in the NCTN member groups. The ultimate goal is to relieve the burdens of illness in patients with cancer through potentially practice changing trials.
|Chumsri, Saranya; Sperinde, Jeff; Liu, Heshan et al. (2018) High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance). Clin Cancer Res 24:3053-3058|
|Gajra, Ajeet; McCall, Linda; Muss, Hyman B et al. (2018) The preference to receive chemotherapy and cancer-related outcomes in older adults with breast cancer CALGB 49907 (Alliance). J Geriatr Oncol 9:221-227|
|Vera Aguilera, Jesus; Rao, Ravi D; Allred, Jacob B et al. (2018) Phase II Study of Everolimus in Metastatic Malignant Melanoma (NCCTG-N0377, Alliance). Oncologist 23:887-e94|
|Tallarico, Michael; Foster, Jared C; Seisler, Drew et al. (2018) Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611). J Geriatr Oncol 9:321-328|
|Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650|
|McCleary, Nadine J; Hubbard, Joleen; Mahoney, Michelle R et al. (2018) Challenges of conducting a prospective clinical trial for older patients: Lessons learned from NCCTG N0949 (alliance). J Geriatr Oncol 9:24-31|
|Woyach, Jennifer A; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med 379:2517-2528|
|Feliciano, Josephine L; Le-Rademacher, Jennifer G; Gajra, Ajeet et al. (2018) Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622). J Geriatr Oncol 9:501-506|
|Rosenkranz, Kari M; Ballman, Karla; McCall, Linda et al. (2018) The Feasibility of Breast-Conserving Surgery for Multiple Ipsilateral Breast Cancer: An Initial Report from ACOSOG Z11102 (Alliance) Trial. Ann Surg Oncol 25:2858-2866|
|King, Rebecca L; Nowakowski, Grzegorz S; Witzig, Thomas E et al. (2018) Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era. Blood Cancer J 8:27|
Showing the most recent 10 out of 98 publications